» Articles » PMID: 33163195

Upregulation of PD-L1 Expression Promotes Epithelial-to-mesenchymal Transition in Sorafenib-resistant Hepatocellular Carcinoma Cells

Overview
Specialty Gastroenterology
Date 2020 Nov 9
PMID 33163195
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The epithelial-to-mesenchymal transition (EMT) status is associated with programmed death-1 ligand 1 (PD-L1) expression in various cancers. However, the role and molecular mechanism of PD-L1 in the EMT of sorafenib-resistant hepatocellular carcinoma (HCC) cells remain elusive. In this study, we aimed to investigate the regulation of PD-L1 on the EMT in sorafenib-resistant HCC cells.

Methods: Initially, the sorafenib-resistant HCC cell lines HepG2 SR and Huh7 SR were established. Western-blot assays were used to detect the expression of PD-L1, E-cadherin, and N-cadherin. The intervention and overexpression of PD-L1 were used to explore the role of PD-L1 in the regulation of EMT in HepG2 SR and Huh7 SR cells. Cell migration and invasion were assessed by transwell assays. PD-L1 or Sterol regulatory element-binding protein 1 (SREBP-1) overexpression and knock-down were performed in order to study the mechanism of PD-L1 in sorafenib-resistant HCC cells.

Results: PD-L1 expression was upregulated, whereas E-cadherin levels were downregulated and N-cadherin expression was increased in HepG2 SR and Huh7 SR cells. The cell viabilities of HepG2 and Huh7 cells were lower than those of HepG2 SR and Huh7 SR cells. PD-L1 overexpression reduced E-cadherin expression and increased N-cadherin levels, whereas PD-L1 knock-down increased E-cadherin expression and decreased N-cadherin expression. PD-L1 expression promoted EMT and the migratory and invasive abilities of HepG2 SR and Huh7 SR cells. PD-L1 promoted the EMT of sorafenib-resistant HCC cells via the PI3K/Akt pathway by activating SREBP-1 expression in HepG2 SR and Huh7 SR cells.

Conclusions: The findings reveal that PD-L1 expression promotes EMT of sorafenib-resistant HCC cells.

Citing Articles

Advances in hepatocellular carcinoma drug resistance models.

Xiang Y, Wu J, Qin H Front Med (Lausanne). 2024; 11:1437226.

PMID: 39144662 PMC: 11322137. DOI: 10.3389/fmed.2024.1437226.


Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis.

Li J, Zhu C, Zhang Z, Zheng X, Wang C, Zhang H Heliyon. 2024; 10(2):e24461.

PMID: 38312647 PMC: 10835185. DOI: 10.1016/j.heliyon.2024.e24461.


Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.

Cho S, Kim W, Yoo D, Han Y, Hwang H, Kim S Sci Rep. 2024; 14(1):1751.

PMID: 38243049 PMC: 10798953. DOI: 10.1038/s41598-024-52160-x.


Regulation and targeting of SREBP-1 in hepatocellular carcinoma.

Su F, Koeberle A Cancer Metastasis Rev. 2023; 43(2):673-708.

PMID: 38036934 PMC: 11156753. DOI: 10.1007/s10555-023-10156-5.


A systems-level analysis of the mutually antagonistic roles of RKIP and BACH1 in dynamics of cancer cell plasticity.

Shyam S, Ramu S, Sehgal M, Jolly M J R Soc Interface. 2023; 20(208):20230389.

PMID: 37963558 PMC: 10645512. DOI: 10.1098/rsif.2023.0389.


References
1.
Chen K, Chen H, Tai W, Feng W, Hsu C, Chen P . Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011; 337(1):155-61. DOI: 10.1124/jpet.110.175786. View

2.
Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T . Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012; 11(12):2348-58. PMC: 3383594. DOI: 10.4161/cc.20811. View

3.
Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

4.
van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F . Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2012; 329(1):74-83. DOI: 10.1016/j.canlet.2012.10.021. View

5.
Qiu X, Hu D, Chen W, Chen R, Qian S, Li C . PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(5 Pt A):1754-1769. DOI: 10.1016/j.bbadis.2018.03.002. View